A Combination Therapy of JO-1 and Chemotherapy in Ovarian Cancer Models

2014 ◽  
Author(s):  
Andre Lieber
Keyword(s):  
Ovarian Cancer ◽  
Combination Therapy ◽  
Cancer Models

scholarly journals An In Vitro and In Vivo Investigation of the Antimetastatic Effects of a Chinese Medicinal Decoction, Erxian Decoction, on Human Ovarian Cancer Models

2012 ◽  
Vol 12 (4) ◽  
pp. 336-346 ◽  
Author(s):  
Ellie S. M. Chu ◽  
Stephen C. W. Sze ◽  
Ho P. Cheung ◽  
Qing Liu ◽  
Tzi B. Ng ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Human Ovarian Cancer ◽  
Erxian Decoction ◽  
Cancer Models

scholarly journals Combination Therapy with DETA/NO and Clopidogrel Inhibits Metastasis in Murine Mammary Gland Cancer Models via Improved Vasoprotection

2018 ◽  
Vol 15 (11) ◽  
pp. 5277-5290 ◽  
Author(s):  
Kseniia Porshneva ◽  
Diana Papiernik ◽  
Mateusz Psurski ◽  
Marcin Nowak ◽  
Rafał Matkowski ◽  
...  
Keyword(s):  
Mammary Gland ◽  
Combination Therapy ◽  
Cancer Models ◽  
Mammary Gland Cancer

scholarly journals Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Hyoung Kim ◽  
Haineng Xu ◽  
Erin George ◽  
Dorothy Hallberg ◽  
Sushil Kumar ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Parp Inhibitor ◽  
Platinum Resistance ◽  
Cancer Models

scholarly journals Current Status of Patient-Derived Ovarian Cancer Models

Cells ◽  
2019 ◽  
Vol 8 (5) ◽  
pp. 505 ◽  
Author(s):  
Yoshiaki Maru ◽  
Yoshitaka Hippo
Keyword(s):  
Ovarian Cancer ◽  
Current Status ◽  
Conventional Chemotherapy ◽  
Cancer Subtypes ◽  
Cancer Models ◽  
Generic Term ◽  
Frequent Failure ◽  
Effective Drugs ◽  
Therapeutic Responses

Ovarian cancer (OC) is one of the leading causes of female cancer death. Recent studies have documented its extensive variations as a disease entity, in terms of cell or tissue of origin, pre-cancerous lesions, common mutations, and therapeutic responses, leading to the notion that OC is a generic term referring to a whole range of different cancer subtypes. Despite such heterogeneity, OC treatment is stereotypic; aggressive surgery followed by conventional chemotherapy could result in chemo-resistant diseases. Whereas molecular-targeted therapies will become shortly available for a subset of OC, there still remain many patients without effective drugs, requiring development of groundbreaking therapeutic agents. In preclinical studies for drug discovery, cancer cell lines used to be the gold standard, but now this has declined due to frequent failure in predicting therapeutic responses in patients. In this regard, patient-derived cells and tumors are gaining more attention in precise and physiological modeling of in situ tumors, which could also pave the way to implementation of precision medicine. In this article, we comprehensively overviewed the current status of various platforms for patient-derived OC models. We highly appreciate the potentials of organoid culture in achieving high success rate and retaining tumor heterogeneity.

scholarly journals Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer

2019 ◽  
Vol 7 (1) ◽  
Author(s):  
Christina A. Hartl ◽  
Adrian Bertschi ◽  
Regina Bou Puerto ◽  
Carolin Andresen ◽  
Emily M. Cheney ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Combination Therapy ◽  
Adaptive Immunity ◽  
Innate And Adaptive Immunity ◽  
Clinical Model

Abstract 1525: SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo

2018 ◽  
Author(s):  
Panagiotis A. Konstantinopoulos ◽  
Graeme Hodgson ◽  
Nisha Rajagopal ◽  
Liv Johannessen ◽  
Joyce F. Liu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Antitumor Activity ◽  
Cancer Models

scholarly journals The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

2019 ◽  
Vol 25 (20) ◽  
pp. 6127-6140 ◽  
Author(s):  
Kalindi Parmar ◽  
Bose S. Kochupurakkal ◽  
Jean-Bernard Lazaro ◽  
Zhigang C. Wang ◽  
Sangeetha Palakurthi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Parp Inhibition ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Cancer Models ◽  
Chk1 Inhibitor
Sign in / Sign up

Export Citation Format

Share Document